Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: A prospective study

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Prospective Study 100%
• Stereotactic Body Radiation Therapy 100%
• Minimal Residual Disease 100%
• Chemoradiotherapy 66%
• Primary Tumor 50%
• Lung 33%
• Tumor 33%
• Radiation Therapy 33%
• Oncology 16%
• Metastatic Carcinoma 16%
• Recurrent Disease 16%
• Equivalent Dose 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Prospective Study 100%
• Non Small Cell Lung Cancer 100%
• Radiation Pneumonia 100%
• Minimal Residual Disease 100%
• Chemoradiation Therapy 66%
• Primary Tumor 50%
• Recurrent Disease 16%